PharmaEngine, Inc. (TPEX: 4162)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
93.60
+0.40 (0.43%)
Jan 20, 2025, 1:30 PM CST
-4.97%
Market Cap 13.68B
Revenue (ttm) 831.92M
Net Income (ttm) 370.14M
Shares Out 143.68M
EPS (ttm) 2.57
PE Ratio 37.04
Forward PE 11.50
Dividend 1.50 (1.60%)
Ex-Dividend Date Aug 12, 2024
Volume 361,035
Average Volume 876,677
Open 93.60
Previous Close 93.20
Day's Range 92.00 - 94.10
52-Week Range 74.80 - 115.00
Beta 0.67
RSI 51.69
Earnings Date Mar 14, 2025

About PharmaEngine

PharmaEngine, Inc., a biopharmaceutical company, engages in the development of drugs and therapeutic drugs for treating cancer in Taiwan. It offers ONIVYDE, a cancer medicine that blocks an enzyme called topoisomerase I, which is involved in copying cell DNA needed to make new cells. The company is developing PEP07, a CHK1 inhibitor, which is in Phase 1 clinical trial for the treatment of hematological tumors and solid tumors. PharmaEngine, Inc. was incorporated in 2002 and is headquartered in Taipei, Taiwan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 4162
Full Company Profile

Financial Performance

In 2023, PharmaEngine's revenue was 767.67 million, an increase of 17.31% compared to the previous year's 654.38 million. Earnings were 274.65 million, a decrease of -13.84%.

Financial Statements

News

There is no news available yet.